ethyl 7-oxo-1,4-dioxaspiro[4.5]decane-8-carboxylate | 813445-32-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ethyl 7-oxo-1,4-dioxaspiro[4.5]decane-8-carboxylate
• 英文别名: 7-oxo-1,4-dioxa-spiro[4.5]decane-8-carboxylic acid ethyl ester
• CAS: 813445-32-8
• 化学式: C₁₁H₁₆O₅
• 分子量: 228.245
• InChiKey: GMBJOJRSMFPIGP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 7-oxo-1,4-dioxaspiro[4.5]decane-8-carboxylate 在 盐酸 、 sodium tetrahydroborate 、 palladium 10% on activated carbon 、 水 、 氢气 、 copper(II) acetate monohydrate 、 1-丙基磷酸酐 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙酸乙酯 为溶剂， 反应 36.5h， 生成 1′-benzyl-5′-ethoxyspiro[cyclohexane-1,3′-indoline]-2′,4-dione
  参考文献：
  名称：

  铜（II）介导的自由基交叉脱氢偶联反应在制备螺环羟吲哚和萨塔普坦的正式全合成中的应用

  摘要：

  据报道，自由基交叉脱氢偶联（CDC）方法可用于制备一系列新型螺环羟吲哚，并已正式合成血管加压素V 2受体拮抗剂Satavaptan。关键步骤涉及简单的线性苯胺前体的铜介导的氧化环化反应，以产生螺环氧吲哚核。这种合成方法也被用于制备新型的Satavaptan支架和类似物。

  DOI：

  10.1016/j.tet.2018.09.026
• 作为产物：
  描述：

  3-乙氧基-2-环己烯-1-酮 在 溶剂黄146 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 38.0h， 生成 ethyl 7-oxo-1,4-dioxaspiro[4.5]decane-8-carboxylate
  参考文献：
  名称：

  Tetrahydroquinazoline Derivatives Useful as Anticancer Agents

  摘要：

  具有一般公式： 这些化合物的制备方法，包含这些化合物的组合物，以及这些化合物的用途。

  公开号：

  US20190248767A1

文献信息

• PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS
  申请人：Dvorak A. Curt

  公开号：US20070032481A1

  公开（公告）日：2007-02-08

  Certain pyrimidine-containing compounds are serotonin receptor modulators useful in the treatment of serotonin-mediated diseases.

  某些含嘧啶的化合物是有效的血清素受体调节剂，可用于治疗血清素介导的疾病。
• N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
  申请人：——

  公开号：US20040259914A1

  公开（公告）日：2004-12-23

  The present application describes modulators of chemokine receptor activity of formula (I): 1 or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, including methods of preparing and intermediates thereof.

  本申请描述了化学式（I）的趋化因子受体活性调节剂或其药用盐形式，用于预防哮喘和其他过敏疾病，以及类风湿性关节炎和动脉粥样硬化等自身免疫病理的药物，包括其制备方法和中间体。
• SUBSTITUTED CYCLOALKENE DERIVATIVE
  申请人：Kimura Tomio

  公开号：US20090233952A1

  公开（公告）日：2009-09-17

  [Object] To provide a substituted cycloalkene derivative having an action to suppress intracellular signal transduction or cell activation induced by endotoxin and to suppress cell responses due to the intracellular signal transduction and cell activation such as an excess generation of inflammatory mediators such as TNF-α, pharmacologically acceptable salts therefor, a medicament containing them as an active ingredient, a preparation method therefor, and a medicament containing the aforementioned substituted cycloalkene derivative as an active ingredient which is superior in prophylaxis and/or treatment of diseases such as sepsis (septic shock, disseminated intravascular coagulation, multiple organ failure and the like), that are associated with intracellular signal transduction or cell activation induced by endotoxin and to cell responses to the intracellular signal transduction and cell activation. [Solution] A compound represented by the general formula (I): wherein X and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A (the ring is 3- to 7-membered heterocyclyl ring or 3- to 7-membered cycloalkyl ring), each represents a hydrogen atom, or X and Y together represent a substituent of ring B. l and m, independently from each other, represent an integer of 0 to 3, and l+m is 1 to 3. R 1 is an aliphatic hydrocarbon group and the like which may be substituted with a group selected from Substituent group β and Substituent group γ. n represents an integer of 0 to 3. R 2 is a C 1 -C 6 alkyl group and the like which may be substituted with a group selected from a hydrogen atom and Substituent group β. R 3 is a phenyl group, 5- to 6-membered heteroaryl group and the like which may be substituted with a group selected from Substituent group ε. R 5 is a C 1 -C 6 alkyl group and the like which may be substituted with a group selected from a hydrogen atom and Substituent group β. Provided that in the case where R 3 is a phenyl group which may be substituted with a group selected from Substituent group ε, X and Y represent a group in which X and Y together with a carbon atom to which they are bound form ring A, or X and Y together represent a substituent of ring B.

  [目的] 提供一种替代环烯烃衍生物，具有抑制内毒素诱导的细胞内信号传导或细胞活化并抑制细胞对细胞内信号传导和细胞活化的反应，例如过量生成TNF-α等炎症介质，其药理学上可接受的盐，包含其作为活性成分的药物，其制备方法以及含有上述替代环烯烃衍生物作为活性成分的药物，其在预防和/或治疗与内毒素诱导的细胞内信号传导或细胞活化以及对细胞内信号传导和细胞活化的反应有关的疾病，例如败血症（败血性休克，弥漫性血管内凝血，多器官衰竭等）方面具有优越性。 [解决方案] 一种由通式（I）表示的化合物：其中，X和Y表示与它们结合的碳原子形成环A（环为3-至7成员的杂环或3-至7成员的环烷基环）的基团，每个表示氢原子，或X和Y一起表示环B的取代基。l和m，独立地，表示0至3的整数，且l+m为1至3。R1是脂肪烃基等，可以被从取代基组β和取代基组γ中选择的基团取代。n表示0至3的整数。R2是C1-C6烷基等，可以被从氢原子和取代基组β中选择的基团取代。R3是苯基，5-至6成员的杂环基等，可以被从取代基组ε中选择的基团取代。R5是C1-C6烷基等，可以被从氢原子和取代基组β中选择的基团取代。但在R3是苯基且可以被从取代基组ε中选择的基团取代的情况下，X和Y表示与它们结合的碳原子形成环A的基团，或X和Y一起表示环B的取代基。
• N-UREIDOALKYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Ko Soo S.

  公开号：US20080132523A1

  公开（公告）日：2008-06-05

  The present application describes modulators of chemokine receptor activity of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, including methods of preparing and intermediates thereof.

  本申请描述了化学式（I）的趋化因子受体活性调节剂或其药学上可接受的盐形式，用于预防哮喘和其他过敏性疾病，以及自身免疫病理学，如类风湿性关节炎和动脉粥样硬化，包括其制备方法和中间体。
• Tetrahydroquinazoline derivatives useful as anticancer agents
  申请人：PFIZER INC.

  公开号：US10590115B2

  公开（公告）日：2020-03-17

  Compounds of the general formula: processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

  通式为 这些化合物的制备工艺、含有这些化合物的组合物以及这些化合物的用途。